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CarboxyterfenadineAbstract In the present study the 2-methylpropanamide and benzamide derivatives of carboxyter-
fenadine, have been synthesized by nucleophilic substitution at carboxylic acid moiety (C-33) of
tertiary carbon C-19 substituted with benzene ring. The proﬁcient and high yielding series was
carried out in two steps by continuous monitoring with TLC. The carboxylic group was utilized
in the formation of 2-methylpropanamide and benzamide derivatives of carboxyterfenadine. The
derivatives were characterized by spectroscopic techniques including mass. The starting material
(2-[4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidino]butyl]phenyl]-2-methylpropanoic acid) itself
is H1 receptor antagonist. Hence, all these compounds A–E were biologically evaluated for antihista-
minic and anticholinergic activity, using isolated guinea pig ileum tissues.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
H1 antagonists are the drugs that competitively inhibit the
action of histamine on tissue containing H1. Usually H1 recep-
tors have been evaluated in vitro in terms of their ability to
inhibit histamine induced spasms in an isolated strip of guinea
pig ileum (Meeves and Appajosyula, 2003). Antihistamines
may be assessed in vivo in terms of their ability to protect ani-
mals against the toxic effects of histamine administered intra-
venously or by aerosol (Suhagia et al., 2006; Saxena et al.,
Figure 1 Fexofenadine.
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nylmethyl)piperidino]butyl] phenyl]-2-methylpropanoic acid)
(Fig. 1) is a selective and peripherally acting H1-receptor
antagonist and is a nonsedative active metabolite of terfena-
dine (see Figs. 2 and 3).
It has a chiral carbon in its chemical structure and is orally
administered as a racemic mixture of R- and S-enantiomers
(Robbins et al., 1998), it has the capacity to exist as Zwitter-
ionic form and does not cross blood–brain barrier (BBB) that
is why it does not cause drowsiness or sedation (Lappin et al.,
2010).
Fexofenadine is used clinically for treating seasonal allergic
rhinitis (Segall et al., 2008) and daily 180 mg of the drug, given
for 2 weeks caused statistical and clinical improvement in
symptoms and less drowsiness in patients with modest to stern
SAR (Hampel et al., 2003). The most common adverse events
were headache, throat irritation, viral infection, nausea, dys-
menorrhea, drowsiness, dyspepsia and fatigue (Markham
and Wagstaff, 1998). Complex of fexofenadine with a-cyclo-
dextrin in aqueous medium was studied which gives the evi-
dence of the attachment of phenyl ring into a-cyclodextrin
cavity (Ali et al., 2012). Thus, it is important to understand
the mechanism of action of fexofenadine in the presence of
chemically active compounds. Fexofenadine has poor bioavail-
ability in humans and its microdose is used to predict the phar-
macokinetics of the therapeutic drug because it has low
intestinal membrane permeability due to hydrophilicity
(Ohura et al., 2012).
In vivo and in vitro antihistaminic studies of fexofenadine
have been established and oral administration on guinea pig
indicates that fexofenadine antagonised histamine-induced
skin wheals in a dose-dependent manner (Neuhaus et al.,
2012; Malick and Grant, 1997). The isolated guinea pig ileum
studies of fexofenadine and terfenadine reveal that both these
compounds have antihistaminic property. Both drugs antagon-
ised the contractile effects of histamine, although, fexofenadine
is more selective anti-histamine than terfenadine (Zhang et al.,
1994).
The present study uses fexofenadine as model compound
and derivatives with hydrazine hydrochloride, urea, p-phenel-
ediamine, acetamide and semicarbazide have been prepared.
In addition, the antihistaminic and anticholinergic activities
of fexofenadine derivatives assessed and compared with fexo-
fenadine and pyrilamine maleate taken as standard for the
examination of biological activities.The carboxylic group at tertiary carbon-19 through con-
densation reaction was esteriﬁed and by nucleophilic substitu-
tion reaction at the acyl (carbonyl) carbon form tetrahedral
intermediate after the elimination of the leaving group it
returns to a carbonyl carbon (Arayne et al., 2009). Various
reactions have been recognized on the basis of the above reac-
tion mechanism by reacting various amines to yield amides
(Sultana et al., 2013).
2. Experimental
2.1. Material and equipments
Fexofenadine was a gift from Getz Pharmaceutical Laborato-
ries Ltd., Karachi, Pakistan. Hydrazine hydrochloride, urea,
p-phenelediamine, acetamide and semicarbazide were of
Merck, Darmstadt, Germany. Acetylcholine chloride (ACh),
pyrilamine maleate, histamine diphosphate and potassium
chloride were purchased from Sigma Chemicals Co, St Louis,
MO, USA, magnesium chloride, magnesium sulfate, potas-
sium dihydrogen phosphate, glucose, calcium chloride, sodium
bicarbonate, sodium dihydrogen phosphate were purchased
from E. Merck, Darmstadt, Germany and sodium chloride
was purchased from BDH Laboratory Supplies, Poole,
England. Analytical grade reagents were used and all the glass-
ware was washed with chromic acid followed by a thorough
washing with freshly prepared de-ionized water, freshly pre-
pared salt solutions were used on the day of the experiment.
Melting points were obtained manually by capillary
method. The IR spectra were obtained on Shimadzu pres-
tige-21 200 VCE coupled to a PIV-PC and loaded with IR
solution version 1.2 software (KBr disks). NMR spectra were
recorded on Bruker FT-NMR 500 MHz with the compounds
dissolved in deuterated methanol. Chemical shifts are reported
in (d ppm) relative to tetramethylsilane as an internal standard.
Signiﬁcant 1H NMR data are tabulated in the order of
multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; and
m, multiplet) and number of protons. Mass spectra were
recorded on Finnign-MAT212 under electron impact (EI)
ionization condition. Thin layer chromatography (TLC) was
performed on HSF-254 TLC plate and compounds visualized
under UV lamp. Tissue bath connected with thermocirculator
which has an inlet and an outlet for salt solutions, tube for
carbogen, ﬁnally connected with transducer, ampliﬁer, oscillo-
graph which monitors the tissue response on chart paper.
2.2. General procedure for preparation of derivatives
Synthesis of amide derivatives of fexofenadine with hydrazine
hydrochloride, urea, p-phenelediamine, acetamide and semi-
carbazide was carried out by adding 0.1 Mole fexofenadine
in 60 mL of methanol with 1:2 drops of concentrated sulfuric
acid and the whole content was reﬂuxed for about 7–8 h. By
continuous monitoring the ﬂask contents, 0.2 M amine solu-
tions were added individually into reaction ﬂask and again
reﬂuxed for about 2–3 h till the completion of the reaction
which was monitored by TLC. Excess solvent was removed
by rotary evaporator and slowly crystallized out of the
solution. The materials were recrystallized in suitable solvents
till constant melting point.
Figure 2 Esteriﬁcation of fexofenadine.
Figure 3 Synthetic pathways of compound A–E.
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Guinea pig (500–550 g) of local breed and either sex were used
for this study. Animals were housed at the animal house of
Aga Khan University Hospital, Karachi, maintained at 23–
25 C and were given a standard diet and tap water. Animals
had free access to water but food was withdrawn 24 h prior
to experiment. Guinea pigs were killed through cervical dislo-
cation. The experiment performed complied with the rulings of
the Institute of Laboratory Animal Resources, Commission of
life Sciences, National Research Council (Ofﬁce of Laboratory
Animal Welfare, 2002).
Male and female guinea pigs were used in the experiment.
Handling and use of animals was according to the Ofﬁce of
Laboratory Animal Welfare policy (Ofﬁce of Laboratory
Animal Welfare, 2002). The animals were housed and fed in
a laboratory kept at constant temperature of 23–25 C understandard conditions i-e 12:12 h light–dark cycle, standard
pellet diet and tap water.
2.4. Isolated guinea pig ileum
Guinea pigs were sacriﬁced by cervical dislocation; ileum was
cut into approximately 2.5-cm segments. Segments were placed
in a carbogen-aerated organ bath (37 C) containing the Tyr-
ode’s solution in mM was: KCl 2.68; NaCl 136.9; MgCl2
1.05; NaHCO3 11.90; NaH2PO4 0.42; CaCl2 1.8 and glucose
5.55, with pH 7.4. One end of the ileal segment was attached
to the transducer (FDT10-A), and the resting tension was
adjusted to a load of 0.5 g. Samples were equilibrated for at
least 30 min before the contraction measurement. The isotonic
contractions were recorded with a Bioscience transducer cou-
pled to a Harvard oscillograph. After equilibration period of
30 min, each tissue preparation was repeatedly treated with
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interval until constant responses were recorded.
2.5. Experimental protocol
After stabilization of the tissues, control peak responses of
acetylcholine chloride (1 lM) and histamine (1 lM) were
obtained and then these spasmogens were repeated in the pres-
ence of increasing concentrations of the compounds A–E
(Willard et al., 1999; Gilani, 1992). Data were analyzed with
Graphpad Prism version 5, GraphPad InStat 3 and expressed
as means ± SEM (Standard error of mean). One way
ANOVA was used to compare the means between groups
followed by Tukey’s test for multiple comparisons.
2.6. Spectral data
1-Fexofenadine: 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmeth-
yl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid, Color:
white, m.p. 190 C, UV nm (e): 1.775(218 nm), IR (KBr) mmax:
3400–3350 db, s, 3058.04 s, 1700 s, 1600 and 1475 sm
1447.60 m, 1403.55 m, 1279 m, 1166.41 m,1099 s, 1068 m,
983, 965 db, sm, 834 ms, 747, 702, 638, 577, 525.53 dp, s.
1H NMR (MeOD, 500 MHz) d: 7.06, 7.19 (m, J= 1.16 Hz),
7.11 (m, J= 0.5 Hz) aromatic, 4.5 (db, J= 1.0 Hz) ACH2
open chain, 4.95 (s) alcoholic, 2.0 NAH, 2.29, 2.19 CH2AN,
2.34 (t, J= 12.2 Hz) ACH2ACH2AN, 2.36 (t, J= 14.0 Hz),
1.39, 1.77 and 1.52 CH3. MS (m/z, %): (500.29, 35.2%) M
+.
Calculated for C32H39NO4: C, 49.14; H, 5.96; N, 3.18. Found:
C, 49.01; H, 5.74; N, 4.33.
Compounds A to E: 2-(A): 2-(4-(1-hydroxy-4-(4-(hydroxydi-
phenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide,
m.p. 115 C, UV nm (e): 171(223 and 259 nm), IR (KBr) mmax:
3350, 3100 cm1 (NAH), 1650 cm1 (C‚O), 1390 cm1
(CAN). 1H NMR (MeOD, 500 MHz) d: 7.19 (m,
J= 7.02 Hz), 7.11 (m, J= 3.5 Hz) and 7.06 aromatic, 6.92
(s, pri amide), 4.41 methine, 2.51, 2.41 CH2AN, 2.2(s) alco-
holic, 1.77 CH3, 1.59, 1.3 (t, J= 6.2 Hz), CH2ACH2AN.
MS (m/z, %): (500, 9.2) M+. Calculated for C32H40N2O3: C,
76.77; H, 8.05; N, 5.6. Found: C, 76.9; H, 7.99; N, 5.4.
3-(B) N,N0-carbonylbis(2-(4-(1-hydroxy-4-(4-(hydroxydiphe-
nylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide),
m.p. 120 C, UV nm (e): 2415 (223 and 259 nm), IR (KBr)
mmax: 3380, 3180 cm1 (NAH), 1650 cm1 (C‚O)
1622 cm1 (NAH bending), 1420 cm1 (CAN). 1H NMR
(MeOD, 500 MHz) d: 9.6 (s, imide), 7.54 (m, J= 3.5 Hz),
7.38 (m, J= 7.02 Hz) and 7.28 aromatic, 3.9 methine, 3.6(s)
alcoholic, 1.8 CH3, 2.5, 1.7 CH2AN, 1.4, 1.3 (t, J= 8 Hz)
CH2ACH2AN. MS (m/z, %): (1026.59, 7.9) M
+. Calculated
for C65H78N4O7: C, 75.99; H, 7.65; N, 5.45. Found: C,
76.01; H, 7.69; N, 5.4.
4-(C) N,N0-(1,4-phenylene)bis(2-(4-(1-hydroxy-4-(4-(hydrox-
ydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropana-
mide), m.p. 229 C, UV nm (e): 5400 (223 and 259 nm), IR
(KBr) mmax: 3390, 3130 cm1 (NAH), 1680 cm1 (C‚O)
1640 cm1 (NAH bending), 1370 cm1 (CAN). 1H NMR
(MeOD, 500 MHz) d: 8 (s, sec amide), 7.64 (m, J= 5.3 Hz),
and 7.22 and 7.11 (m, J= 6 Hz) aromatic, 4.6 methine,
3.65(s) alcoholic, 2.75, 2.41 CH2AN, 1.6, 1.27 (t, J= 4.2 Hz)
CH2ACH2AN, 1.24 CH3. MS (m/z, %): (1074.62, 6.5) M
+.Calculated for C70H82N4O6: C, 78.18; H, 7.69; N, 5.21. Found:
C, 78.01; H, 7.61; N, 5.29.
5-(D) N-carbamoyl-2-(4-(1-hydroxy-4-(4-(hydroxydiphe-
nylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide,
m.p. 125 C, UV nm (e): 4090 (216 and 246 nm), IR (KBr)
mmax: 3380, 3178 cm1 (NAH), 1600–1630 cm1 (C‚O)
1625 cm1 (NAH bending), 1570 cm1 (CAN). 1H NMR
(MeOD, 500 MHz) d 8.8 (s, imide), 7.7 (m, J= 3.5 Hz), 7.46
(m, J= 7.02 Hz), 7.22 aromatic, 5.7 (s, urea) 3.7 methine,
3.2(s) alcoholic, 3.1, 2.6 CH2AN, 1.8 CH3, 1.6, 1.5
(t, J= 4.1 Hz) CH2ACH2AN. MS (m/z, %): (586.32, 8.5)
M+. Calculated for C34H42N4O5: C, 69.60; H, 7.22; N, 9.55.
Found: C, 69.4; H, 7.31; N, 9.71.
6-(E) N-(2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmeth-
yl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoyl)benzamide,
m.p. 79 C, UV nm (e): 5740 (202 and 234 nm), IR (KBr)
mmax: 3200, 3190 cm1 (NAH), 1620 cm1 (C‚O),
1670 cm1 (NAH bending), 1545 cm1 (CAN). 1H NMR
(MeOD, 500 MHz) d: 9.5 (s, imide), 8.08 aromatic, 7.28 (s,
J= 3.5 Hz), 7.23 (s, J= 7.02 Hz), 2.1, 3.5 CH2AN, 2.32
methine, 3.65(s) alcoholic, 1.63, 1.58 CH3, 1.35 (t, J= 4.1 Hz)
CH2ACH2AN. MS (m/z, %): (604.33, 5.8) M
+. Calculated
for C32H44N2O4: C, 77.45; H, 7.33; N, 4.63. Found: C,
77.20; H, 7.31; N, 4.38.
2.7. Spectral analysis
In the IR spectra of fexofenadine, the OH stretching vibration
of carboxylic acid appeared as a broadband ranging from 3400
to 3350 cm–1 and CAH stretching at 3058 cm–1, fexofenadine
showed a strong band at 1700 cm–1 due to C‚O stretching
and at 1279 cm–1 for CAO stretching. C‚C aromatic strong
bands were observed at 1475 and 1600 cm–1, while in all com-
pounds from A to E the hydroxyl peak of acid was modiﬁed
and changed into broad to sharp band. The spectra of all
the compounds showed the absence of acidic OH peak and
amide has been formed. 1H NMR data supported the evidence
of amide formation. The methyl groups of tertiary carbon and
acidic proton have been shifted while other signals of fexofen-
adine were present. All compounds A to E showed a singlet in
the region 6.9–9.5 ppm which provide evidence for the absorp-
tion of amide. In addition, the spectral data also mentioned
other signals consequent to the particular chemical structure
of the compounds. All the compounds showed very low
percentage of (M+) peak because they were not as sturdy as
fexofenadine. The electron impact mass spectrum (EIMS) of
fexofenadine showed molecular ion (M+) peak at (m/z, %):
(320, 35).
2.8. Effect on guinea-pig ileum
Fexofenadine a non-anticholinergic, non-sedative antihista-
mine (Caballero et al., 1996) is prescribed for oral treatment
of allergic rhinitis and chronic urticaria (Amichai et al.,
2001). The nonsedating fexofenadine is actually an active
metabolite of terfenadine (Turncliff et al., 2006; Amon et al.,
2000), a drug taken off the market because of its cardio toxic-
ity. Recent data subjected to indicate whether the compounds
A–E are antihistaminic and anticholinergic in nature or not.
The Guinea pig ileum is commonly used to deﬁne whether a
Figure 4 A tracing showing the inhibitory effect of 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-
methylpropanamide.
Figure 5 Inhibitory effect of histamine (1 lM) responses in the presence of compound A–E on the guinea-pig ileum. Value shown are
mean ± S.E.M, n= 6. (*P< 0.05; **P< 0.0001; compared with control group; One way ANOVA, Tukey’s multiple comparison).
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2007).
It is envisaged that all compounds are antihistaminic in nat-
ure but they did not block acetylcholine chloride (Fig. 4). The
effect of different doses of fexofenadine was same to pyrila-
mine a standard histamine receptor (H1) antagonist for block-
ing the contractile effect of the guinea pig ileum while the
acetylcholine chloride stimulant effects were not blocked
(Corco´stegui et al., 2006).In guinea-pig ileum, compounds A–E inhibit the histamine
(1 lM) responses at dose 3–100 lM/mL (Fig. 4). Compound
A: A dose of 3 lM/ml 81.67 ± 3.827%, 10 lM/ml
69.50 ± 5.920% and 30 lM/ml 47.00 ± 4.382% and complete
inhibition obtained at a dose of 100 lM/ml 11.33 ± 1.783.
Compound B: A dose of 3 lM/ml 65.83 ± 7.935%, 10 lM/
ml 53.00 ± 3.759% and 30 lM/ml 41.67 ± 4.580% and com-
plete inhibition obtained at a dose of 100 lM/ml
12.67 ± 2.728 (see Fig. 5).
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ml 54.50 ± 8.094% and 30 lM/ml 45.00 ± 2.933% and com-
plete inhibition obtained at a dose of 100 lM/ml 15.17 ±
3.978. Compound D: A dose of 3 lM/ml 70.83 ± 10.85%,
10 lM/ml 57.17 ± 5.700% and 30 lM/ml 45.00 ± 4.494%
and complete inhibition obtained at a dose of 100 lM/ml
18.00 ± 4.258. Compound E: A dose of 3 lM/ml 74.83 ±
2.833%, 10 lM/ml 54.17 ± 3.978% and 30 lM/ml
36.83 ± 3.016% and complete inhibition obtained at a dose
of 100 lM/ml 18.00 ± 4.258. And its parent compound fexo-
fenadine cause inhibition of histamine (1 lM) responses at
dose 0.000003 lM/ml 23.14+ 4.48, 0.00001 lM/ml 40.87+ 8.98,
0.00003 lM/ml 51.87 + 11.74, 0.0001 lM/ml 89.05 + 1.28
and 0.0003 lM/ml cause complete inhibition. Similar patterns
of inhibition were seen with pyrilamine at dose 0.03 lM/ml
13.52 + 7.83%, 0.1 lM/ml 70.96 + 7.05%, 0.3 lM/ml
88.69 + 1.84% and the 1.0 show the complete inhibition of
histamine (1 lM) responses.
3. Conclusion
The current study was the ﬁrst attempt in which ﬁve deriva-
tives (2-methylpropanamide and benzamide) of fexofenadine
were synthesized, characterized by TLC, IR, UV, NMR and
mass spectroscopy. The antihistaminic and anticholinergic
mechanisms were tested on guinea pig ileum. The compounds
A–E have antihistaminic action but not anticholinergic as
shown by the tissue response.
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